Seth Fagbemi, MD
Hematology & Oncology · Marshfield, WINPI 1205922374
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,210 of the $3,408 with a category attached, or 94.2%. Every reported general payment came from a single manufacturer, Gilead. Reporting peaked in 2022 at $1,680 and has fallen 93.0% since, to $118 in 2025.
Across 4 payments — averaging $851.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
Across 13 payments — averaging $1470.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$10K
- Amgen$9K
- Merck$167
What the payments were for
- Consulting fees$3,21094%
- Food & beverage$1986%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 4 | $3,408 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecartus$3,210
How this compares
$3,408 in reported general payments places this provider in the 70th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 35 | $531,950 |
| CabometyxCabozantinib S-Malate | 16 | $396,702 |
| TasignaNilotinib Hcl | 16 | $171,413 |
| EliquisApixaban | 11 | $15,438 |
| Abiraterone Acetate | 67 | $9,654 |
| Imatinib Mesylate | 33 | $9,392 |
| Exemestane | 45 | $3,032 |
| Anastrozole | 79 | $1,177 |
| Prednisone | 92 | $736 |
| Prochlorperazine Maleate | 46 | $647 |
| Tamoxifen Citrate | 22 | $495 |
| Hydroxyurea | 28 | $457 |
| Dexamethasone | 55 | $389 |
| Ondansetron Hcl | 15 | $375 |
| Oxycodone Hcl | 12 | $186 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Marshfield
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
- Guru Subramanian Guru MurthyMilwaukee$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.